Loading organizations...
§ Private Profile · Kfar Saba, HaMerkaz, Israel
Medical technology company providing FFR guidance from angiograms for interventional cardiology, focused on optimizing PCI therapy.
Based in Kfar Saba, Israel, CathWorks develops medical technology tools that provide non-invasive fractional flow reserve guidance from routine angiograms to optimize percutaneous coronary intervention decisions. The company's primary product, the FFRangio System, creates three-dimensional reconstructions of coronary arteries to support physicians and hospital networks during complex interventional cardiology procedures. After receiving FDA clearance in 2018, the enterprise secured a $30 million Series C financing round the following year, bringing its total venture funding to over $45 million. Under the leadership of Chief Executive Officer Ramin Mousavi, the medical device manufacturer attracted investment from prominent institutional backers including Deerfield Capital Management before ultimately being acquired by Medtronic in a transaction valued at $585 million. Prior to this acquisition, the system also achieved national reimbursement status in Japan. CathWorks was founded in 2013 by Ran Kornowski, Guy Lavi, and Ifat Lavi.
CathWorks has raised $45.8M across 2 funding rounds.
CathWorks has raised $45.8M in total across 2 funding rounds.
CathWorks has raised $45.8M across 2 funding rounds. Most recently, it raised $30.0M Series C in February 2019.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 4, 2019 | $30M Series C | Andrew ElBardissi, MD | — | Announced |
| Oct 2, 2017 | $15.8M Series B | Quark Venture, Triventures | BioStar Ventures, Planven Entrepreneur Ventures, Pontifax | Announced |
CathWorks has raised $45.8M in total across 2 funding rounds.
CathWorks's investors include Andrew ElBardissi, MD, Quark Venture, Triventures, BioStar Ventures, Planven Entrepreneur Ventures, Pontifax.